Cardiac Imaging
RapidAI may be more accurate than VizAI in detecting large vessel occlusion
RapidAI automated imaging appeared to be more accurate than VizAI in detecting cases of large vessel occlusion, as well as in identifying those missed by its counterpart among individuals with acute stroke, results of a comparative analysis show.
AI stands to change cardiology practice, but guidance, evidence of benefit are needed
Editor’s Note: This is part one of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy .
FDA clears software to reduce ‘guesstimation’ when assessing atherosclerotic risk
Elucid announced it received 510(k) clearance from the FDA for its noninvasive imaging analysis software to help quantify and classify plaque morphology and diagnose CVD.
FDA approves novel PET radiotracer for evaluation of suspected MI, ischemia
The FDA approved 18F flurpiridaz, a new cardiac PET perfusion radiotracer, for adult patients with known or suspected coronary artery disease being evaluated for myocardial ischemia and infarction.
FDA approves 160 cm endovascular navigation wire with 3D imaging guidance
Philips announced the FDA approved the 160 cm version of its endovascular navigation wire that uses fiber optic technology.
FDA clears upgraded AI for detection, scoring of coronary calcium
Nanox announced its subsidiary, Nanox.AI, received FDA 510(k) clearance for its AI-powered coronary artery disease detection solution.
AI could improve diagnostic scope of routine coronary angiography
AI accurately predicted several measures of cardiac function from coronary angiography that would otherwise require additional tests such as echocardiography or catheterization, a speaker reported.
FDA-cleared AI app for point-of-care diagnosis of heart failure launched
Exo announced the launch of its FDA-cleared AI imaging applications for the diagnosis of heart failure on its handheld ultrasound device.
Acoramidis may improve cardiac mass, function in transthyretin amyloid cardiomyopathy
ATLANTA — Data from a small substudy with cardiac MRI suggest acoramidis may improve both cardiac mass and function for adults with symptomatic transthyretin amyloid cardiomyopathy, building on previous positive data, researchers reported.
PCI may benefit patients with unblocked arteries but vulnerable plaque vs. medical therapy
ATLANTA — Preventive PCI plus optimal medical therapy was superior to optimal medical therapy alone for patients with nonflow-limiting vulnerable coronary plaques, according to the results of the PREVENT trial.